NEW You can now listen to Fox News articles!
According to a recent study published in The New England Journal of Medicine, a once-a-week diabetes drug causes dramatic weight loss in obese people. The study authors said participants in the 72-week trial lost up to 20% of their body weight.
“The results indicate that tirzepatide may be a potential therapeutic option for people living with obesity, with participants losing between 16% and 22.5% of their initial weight,” said the authors of the study. study.
The drug, tirzepatide, is a new drug that was recently approved by the Food & Drug Administration to help treat type 2 diabetes with a weekly injection. The drug works with two hormones that help control blood sugar and send signals of fullness to the brain, the authors said in the study. Researchers decided to examine the effect of the drug on diabetes on obesity and presented the results of the phase 3 trial at a symposium at the 82nd Scientific Sessions of the American Diabetes Association® (ADA) in Nova Orleans, LA.
Obese person measuring his belly. (Credit: iStock)
KIM KARDASHIAN’S CRASH DIET COULD GIVE MORE WEIGHT GAIN: HEALTH EXPERTS
The 72-week controlled, randomized, double-blind trial included more than 2,500 participants who considered themselves obese and had no diabetes.
The research team divided the participants into four groups. Three of the groups were given 5mg, 10mg or 15mg of tirzepatide to be self-administered once a week for 72 weeks, while the fourth group was given a self-administered placebo injection. All four groups received counseling sessions on low-calorie living habits and meals. They also did at least 150 minutes of physical activity a week.
The researchers found that 89% of participants, who took the 5 mg dose of the drug and 96% of those who took the weekly dose of 10 mg and 15 mg of the drug, achieved at least a reduction in body weight. 5% compared to 28% of those. in the placebo group.
A drug designed to treat cholesterol has been found to reduce coronavirus infection by 70% in laboratory studies, and researchers are now calling for additional clinical trials among patients hospitalized with COVID-19. (iStock)
According to the report, participants who took the 5 mg dose of tirzepatide lost an average of 35 pounds, and the 10 mg group achieved an average loss of 49 pounds. Participants taking the 15 mg injection saw an average weight loss of 52 pounds during the 72 weeks of the study. Those in the placebo group achieved an average weight loss of 5 pounds, according to the study.
PERSON IS LOST WEIGHT FOR HEALTH BENEFITS, NOT FOR PHYSICAL APPEARANCE: MAYO CLINIC SURVEY
“Obesity should be treated like any other chronic disease, with effective and safe approaches targeting the underlying mechanisms of the disease, and these results underscore that tirzepatide may be doing just that,” said lead researcher Ania Jastreboff. , MD, PhD, Associate Professor at Yale University School. of Medicine and the director of Weight Management and Obesity Prevention at the Yale Stress Center told a media outlet.
Man during gym bench press exercise (iStock)
“These results are an important step forward in the potential expansion of effective treatment options for obese people. In particular, approximately 9 out of 10 obese people lost weight while taking tirzepathide,” said Jastreboff, who is also co-director. of the Yale Center for Weight Management in Connecticut told the media report.
CLICK HERE TO GET THE FOX NEWS APP
According to the Centers for Disease Control and Prevention (CDC), the prevalence of obesity in the United States was nearly 42% in 2017 through March 2020. The CDC stated that conditions related to obesity Obesity includes heart disease, stroke, type 2 diabetes and some types of cancer.